During the Digestive Disease Week meeting, AbbVie presented late-breaking data analyses that showed both doses of Skyrizi met the co-primary endpoints of clinical remission and endoscopic response at week 12 compared to placebo in two Phase III studies. The Lancet published results from pivotal global Phase III clinical trials – Measure Up 1, Measure Up 2 and AD Up – evaluating Rinvoq (upadacitinib) in adults and adolescents with mild to severe atopic dermatitis who were candidates for systemic treatment.

Bristol Myers Squibb announced a new analysis of data from the Phase 3 EXPLORER-HCM study evaluating mavacamten, an investigational, first-in-class cardiac myosin inhibitor, in patients with obstructive hypertrophic cardiomyopathy (oHCM), which was presented at the American College of Cardiology’s 70th Annual Scientific Session with simultaneous publication in The Lancet.

Prime Minister Narendra Modi sounded the alarm over the rapid spread of Covid-19 through India’s vast countryside on May 14, as 4,000 people died from the virus for the third straight day and total infections crossed 24 million.

The same group at the University of Oxford and the Jenner Institute that developed the AstraZeneca-Oxford Covid-19 vaccine reported that their investigational malaria vaccine, R21/Matrix-M, demonstrated 77 percent efficacy in children over 12 months of follow-up.

The majority of people who have had Covid-19 are protected from getting it again for at least six months, a study published on March 17 showed, but older people are more prone to reinfection than younger people.

Clover Biopharmaceuticals raised a $230 million series C round co-led by GL Ventures and Temasek, which will push the Chinese fusion protein company’s Covid-19 vaccine into Phase II/III testing and production planning.

Public Health England (PHE) published real-world analyses of people in the U.K. who had received the first shot of the Pfizer-BioNTech Covid-19 vaccine, with the data – which were published in The Lancet – showing that there was a decrease of about 70 percent in infections among healthcare workers after the first shot.

AstraZeneca and Oxford University’s Covid-19 vaccine is more effective when its second dose is given three months after the first, instead of six weeks, a peer-reviewed study published in The Lancet medical journal showed on Feb. 19.

As the world awaits the production and distribution of hundreds of millions of doses of COVID-19 vaccines that have been granted emergency use authorization, biopharmaceutical companies and manufacturers are developing the next wave of vaccines and therapeutics to combat the pandemic.

Oxford University and AstraZeneca’s Covid-19 vaccine showed in a study it had 76% efficacy against symptomatic infection for three months after a single dose, which increased if the second shot is delayed, backing Britain’s vaccine rollout policy.